Thread: Mitsubishi Tanabe bags NeuroDerm and its PhIII Parkinson's program for $1.1B - Endpoi
View Single Post
Old 07-25-2017, 01:50 AM
NewsBot NewsBot is offline
News Gatherer
Community Support Team
  
Join Date: Dec 2007
Posts: 65,355
15 yr Member
NewsBot NewsBot is offline
News Gatherer
Community Support Team
 
Join Date: Dec 2007
Posts: 65,355
15 yr Member
Post Mitsubishi Tanabe bags NeuroDerm and its PhIII Parkinson's program for $1.1B - Endpoi

Endpoints News

Mitsubishi Tanabe bags NeuroDerm and its PhIII Parkinson's program for $1.1B
Endpoints News
The Japanese pharma company agreed to pay $1.1 billion for the biotech, which has been developing a lead program for continued dosing of levodopa/carbidopa for Parkinson's patients. That's $39 a share, or a 79% premium over the unaffected early June ...
Mitsubishi Tanabe to Buy Parkinson's Disease Drugs Firm NeuroDerm for $1.1BGenetic Engineering & Biotechnology News
Mitsubishi Tanabe Coughs Up $1.1 Billion Cash for Parkinson's Biotech NeuroDermPharmaLive (press release) (subscription)
Why NeuroDerm Ltd Acquired a Higher Price TodayMadison.com
PMLiVE -Medical Xpress -The Jewish Press - JewishPress.com
all 33 news articles »


More...
NewsBot is offline   Reply With QuoteReply With Quote